Peijun Wang1,2,3, Zhenzhen Li1, Song Ren2,3, Jiangwei Li1,2,3, Jun Yang1,2,3, Guangyao Kong4,5,6, An Jiang7,8,9, Zongfang Li10,11,12. 1. National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an, 710004, Shaanxi Province, China. 2. Shaanxi Provincial Clinical Research Center for Hepatic and Splenic Diseases, Xi'an, 710004, Shaanxi Province, China. 3. Department of Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi Province, China. 4. National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an, 710004, Shaanxi Province, China. gyk@live.com. 5. Shaanxi Provincial Clinical Research Center for Hepatic and Splenic Diseases, Xi'an, 710004, Shaanxi Province, China. gyk@live.com. 6. Department of Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi Province, China. gyk@live.com. 7. National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an, 710004, Shaanxi Province, China. doctorj@126.com. 8. Shaanxi Provincial Clinical Research Center for Hepatic and Splenic Diseases, Xi'an, 710004, Shaanxi Province, China. doctorj@126.com. 9. Department of Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi Province, China. doctorj@126.com. 10. National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an, 710004, Shaanxi Province, China. lzf2568@mail.xjtu.edu.cn. 11. Shaanxi Provincial Clinical Research Center for Hepatic and Splenic Diseases, Xi'an, 710004, Shaanxi Province, China. lzf2568@mail.xjtu.edu.cn. 12. Department of Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi Province, China. lzf2568@mail.xjtu.edu.cn.
Abstract
BACKGROUND: Hematopoietic abnormality is a common cause of cirrhotic hypersplenism (CH) complications and death; it causes serious adverse effects and is associated with bleeding, anemia, infection in CH patients. However, the underlying mechanism is unclear. AIMS: We aimed to investigate the effects of the spleen on hematopoiesis and hematopoietic stem/progenitor cells (HSPCs) in CH patients. METHODS: Eleven CH patients were enrolled to assess the effects of the spleen on HSPC functions. Hematopoietic changes were examined by flow cytometry analysis. HSPC functions were detected with colony-forming assays and in vitro cell cultures. Enzyme-linked immunosorbent assay (ELISA) was used to test the concentration of epithelial growth factor (EGF). RESULTS: The number of HSPCs was decreased in CH patients and was rescued after splenectomy. Serum from CH patients dysregulated HSPCs function, and serum from splenectomy patients restored the dysregulated HSPC function in vitro. The concentration of EGF was decreased in CH patients and was restored to normal level after splenectomy. EGF rescued the dysregulated HSPCs function in vitro. CONCLUSIONS: The spleen can regulate the functions of HSPCs in CH patients by regulating EGF signaling. EGF may be a therapeutic target for CH treatment.
BACKGROUND:Hematopoietic abnormality is a common cause of cirrhotic hypersplenism (CH) complications and death; it causes serious adverse effects and is associated with bleeding, anemia, infection in CH patients. However, the underlying mechanism is unclear. AIMS: We aimed to investigate the effects of the spleen on hematopoiesis and hematopoietic stem/progenitor cells (HSPCs) in CH patients. METHODS: Eleven CH patients were enrolled to assess the effects of the spleen on HSPC functions. Hematopoietic changes were examined by flow cytometry analysis. HSPC functions were detected with colony-forming assays and in vitro cell cultures. Enzyme-linked immunosorbent assay (ELISA) was used to test the concentration of epithelial growth factor (EGF). RESULTS: The number of HSPCs was decreased in CH patients and was rescued after splenectomy. Serum from CH patients dysregulated HSPCs function, and serum from splenectomy patients restored the dysregulated HSPC function in vitro. The concentration of EGF was decreased in CH patients and was restored to normal level after splenectomy. EGF rescued the dysregulated HSPCs function in vitro. CONCLUSIONS: The spleen can regulate the functions of HSPCs in CH patients by regulating EGF signaling. EGF may be a therapeutic target for CH treatment.
Authors: Madhava Pai; Dimitris Zacharoulis; Miroslav N Milicevic; Salah Helmy; Long R Jiao; Natasa Levicar; Paul Tait; Michael Scott; Stephen B Marley; Kevin Jestice; Maria Glibetic; Devinder Bansi; Shahid A Khan; Despina Kyriakou; Christos Rountas; Andrew Thillainayagam; Joanna P Nicholls; Steen Jensen; Jane F Apperley; Myrtle Y Gordon; Nagy A Habib Journal: Am J Gastroenterol Date: 2008-07-12 Impact factor: 10.864
Authors: Laurent Spahr; Yves Chalandon; Sylvain Terraz; Vincent Kindler; Laura Rubbia-Brandt; Jean-Louis Frossard; Romain Breguet; Nicolas Lanthier; Annarita Farina; Jakob Passweg; Christoph D Becker; Antoine Hadengue Journal: PLoS One Date: 2013-01-14 Impact factor: 3.240
Authors: Phuong L Doan; Heather A Himburg; Katherine Helms; J Lauren Russell; Emma Fixsen; Mamle Quarmyne; Jeffrey R Harris; Divino Deoliviera; Julie M Sullivan; Nelson J Chao; David G Kirsch; John P Chute Journal: Nat Med Date: 2013-02-03 Impact factor: 53.440